Avanos Medical (AVNS) Enterprise Value (2013 - 2026)

Avanos Medical (AVNS) has 14 years of Enterprise Value data on file, last reported at -$65.6 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value rose 32.37% year-over-year to -$65.6 million; the trailing twelve-month figure through Mar 2026 stood at -$65.6 million (up 32.37% YoY), and the FY2025 full-year result was -$89.8 million, up 16.62% from the prior year.
• Enterprise Value climbed to -$65.6 million in Q1 2026, from -$89.8 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$65.6 million in Q1 2026 to a low of -$127.7 million in Q4 2022.
• A 5-year average of -$94.5 million and a median of -$92.2 million in 2024 frame the typical range for Enterprise Value.
• Across the five-year window, Enterprise Value declined 27.97% in 2025 and soared 32.37% in 2026, its largest moves.
• Tracing AVNS's Enterprise Value over 5 years: stood at -$127.7 million in 2022, then jumped by 31.32% to -$87.7 million in 2023, then slipped by 22.81% to -$107.7 million in 2024, then grew by 16.62% to -$89.8 million in 2025, then advanced by 26.95% to -$65.6 million in 2026.
• Business Quant data shows AVNS's Enterprise Value at -$65.6 million in Q1 2026, -$89.8 million in Q4 2025, and -$70.5 million in Q3 2025.